Overview

  • Product nameMiTMAB™
  • Description
    Cell permeable dynamin I and dynamin II inhibitor
  • Biological descriptionCell permeable dynamin I and dynamin II inhibitor (IC50 = 3.1 and 8.4 µM for inhibition of dynamin I and dynamin II GTPase respectively). Targets the pleckstrin homology (PH) (lipid binding) domain. Competitive with phospholipid and noncompetitive with GTP. Inhibits receptor-mediated and synaptic vesicle endocytosis (IC50 values are 19.9 and 2.2 µM respectively). Inhibits cancer cell growth.
  • General notes

    Sold under exclusive licence from Children's Medical Research Institute and Newcastle Innovation Ltd. MiTMAB™ is a trademark of Children's Medical Research Institute and Newcastle Innovation Ltd

Properties

    Applications

    Our Abpromise guarantee covers the use of ab120466 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Notes
    Functional Studies Use at an assay dependent concentration.

    MiTMAB™ images

    • ab66705 staining PAI1 in HeLa cells treated with MiTMAB™ (ab120466), by ICC/IF. Increase in PAI1 expression correlates with increased concentration of MiTMAB™, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120466 (MiTMAB™) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab66705 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

    References for MiTMAB™ (ab120466)

    This product has been referenced in:
    • Harper CB  et al. Targeting membrane trafficking in infection prophylaxis: dynamin inhibitors. Trends Cell Biol 23:90-101 (2013). Read more (PubMed: 23164733) »
    • Joshi S  et al. The dynamin inhibitors MiTMAB and OcTMAB induce cytokinesis failure and inhibit cell proliferation in human cancer cells. Mol Cancer Ther 9:1995-2006 (2010). Read more (PubMed: 20571068) »
    • Quan A  et al. Myristyl trimethyl ammonium bromide and octadecyl trimethyl ammonium bromide are surface-active small molecule dynamin inhibitors that block endocytosis mediated by dynamin I or dynamin II. Mol Pharmacol 72:1425-39 (2007). Read more (PubMed: 17702890) »
    • Hill TA  et al. Long chain amines and long chain ammonium salts as novel inhibitors of dynamin GTPase activity. Bioorg Med Chem Lett 14:3275-8 (2004). Read more (PubMed: 15149689) »

    See 1 Publication for this product

    Product Wall

    There are currently no Questions for ab120466.
    Please use the link above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"